ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

VIRX Viracta Therapeutics Inc

0,8102
-0,0298 (-3,55%)
03 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Viracta Therapeutics Inc VIRX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,0298 -3,55% 0,8102 23:16:11
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,8212 0,80 0,84 0,8102 0,84
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
15.4.202414:00GLOBEViracta Therapeutics Announces Positive Topline Nana-val..
01.4.202414:30GLOBEViracta Therapeutics to Present Topline Nana-val Results..
07.3.202423:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
07.3.202422:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
07.3.202422:12EDGAR2Form 8-K - Current report
07.3.202422:05GLOBEViracta Therapeutics Reports Fourth Quarter and Full Year..
29.2.202414:00GLOBEViracta Therapeutics Announces Completion of Second-Stage..
28.2.202402:40EDGAR2Form 144 - Report of proposed sale of securities
28.2.202401:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.2.202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14.2.202403:04EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06.2.202422:05GLOBEViracta Therapeutics to Present at the Oppenheimer 34th..
04.1.202414:00GLOBEViracta Therapeutics Provides Clinical Update and Outlook..
12.12.202314:00GLOBEViracta Therapeutics Announces Orphan Drug Designation..
04.12.202322:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.12.202314:30GLOBEViracta Therapeutics Announces Interim Data from Phase 1b/2..
29.11.202301:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.11.202301:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.11.202323:30EDGAR2Form 8-K - Current report
09.11.202322:32EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.11.202314:30EDGAR2Form 8-K - Current report
09.11.202314:30GLOBEViracta Therapeutics Reports Third Quarter 2023 Financial..
07.11.202322:15GLOBEViracta Therapeutics to Present at Upcoming Investor..
04.10.202313:01EDGAR2Form 8-K - Current report
04.10.202313:00GLOBEViracta Therapeutics to Host R&D Day Highlighting Nana-val..
05.9.202315:00GLOBEViracta Therapeutics to Host R&D Day on October 4, 2023
30.8.202300:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.8.202300:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.8.202322:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.8.202322:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.8.202322:05GLOBEViracta Therapeutics Announces New Employment Inducement..
16.8.202323:58EDGAR2Form 3 - Initial statement of beneficial ownership of..
14.8.202322:35EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.8.202314:02EDGAR2Form 8-K - Current report
14.8.202314:00GLOBEViracta Therapeutics Reports Second Quarter 2023 Financial..
08.8.202314:30GLOBEViracta Therapeutics Announces Publication in Blood Advances..
07.8.202313:36EDGAR2Form 8-K - Current report
07.8.202313:30GLOBEViracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D...
28.6.202314:00GLOBEViracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves..
31.5.202322:15GLOBEViracta Therapeutics to Present at the Jefferies Healthcare..
11.5.202322:05GLOBEViracta Therapeutics to Present at the RBC Capital Markets..
08.5.202322:05GLOBEViracta Therapeutics Reports First Quarter 2023 Financial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock